Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

RAY1225

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Guangdong Raynovent Biotech Co · Phase 1 · Completed · Enrollment 68

NCT05835752

ArmPopulationDoseWeeksEstimandWeight change
RAY1225(Part A)Obese; Healthyn/rn/rn/rn/r
Placebo (Part A)Obese; Healthyn/rn/rn/rn/r
RAY1225 (Part B)Obese; Healthyn/rn/rn/rn/r
Placebo (Part B)Obese; Healthyn/rn/rn/rn/r
RAY1225(Part C)Obese; Healthyn/rn/rn/rn/r
Placebo (Part C)Obese; Healthyn/rn/rn/rn/r